Aizon Secures $20M in Series C Funding Led by NewVale Capital to Enhance Pharma Manufacturing Outcomes
Aizon, an Artificial Intelligence (AI) SaaS provider that transforms pharmaceutical manufacturing operations, today announced that it has closed $20 million in Series C funding led by NewVale Capital, a growth equity fund that invests in proven, revenue-generating service businesses in pharmaceuticals and biotechnology. Existing investors Atlantic Bridge, Crosslink Capital, and Uncork Capital also participated in the round. This infusion of capital, combined with the continued support of key investment partners, will enable Aizon to significantly scale, accelerate its development pipeline, and better serve its customers.
Aizon leverages advanced predictive analytics, artificial intelligence, and other smart factory technologies to provide the most powerful and accessible GMP AI platform for pharmaceutical manufacturers. With Aizon, customers unlock next-generation insights and enhanced decision-making capabilities and can discover new optimisation paths, reduce costs, predict deviations, and enhance their manufacturing systems. Aizon prioritises rigorous quality and compliance and follows GAMP5 for GMP processes to ensure compliant data acquisition, storage, and consumption.